Completed PHASE2 INTERVENTIONAL 4-arm NCT01940146

Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis

Sponsor: Sun Pharma Advanced Research Company Limited

Interventions SPARC Placebo SPARC1310 I SPARC1310 II SPARC1310 III

Updated 10 times since 2017 Last updated: May 2, 2019 Started: Oct 31, 2014 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Seasonal Allergic Rhinitis, this trial is completed. The trial is conducted by Sun Pharma Advanced Research Company Limited and has accumulated 10 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Jun 2019 — Jan 2021 [monthly]

Completed PHASE2
Dec 2018 — Jun 2019 [monthly]

Completed PHASE2
Jun 2018 — Dec 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Pharma Advanced Research Company Limited

Data source: Sun Pharma Advanced Research Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kingston, Canada